Stocks and Investing
Stocks and Investing
Mon, February 14, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jeffrey Zekauskas Maintained (CC) at Hold with Decreased Target to $30 on, Feb 14th, 2022
Jeffrey Zekauskas of JP Morgan, Maintained "The Chemours Company" (CC) at Hold with Decreased Target from $35 to $30 on, Feb 14th, 2022.
Jeffrey has made no other calls on CC in the last 4 months.
There are 2 other peers that have a rating on CC. Out of the 2 peers that are also analyzing CC, 1 agrees with Jeffrey's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Joshua Spector of "UBS" Maintained at Hold with Increased Target to $36 on, Tuesday, January 4th, 2022
This is the rating of the analyst that currently disagrees with Jeffrey
- Arun Viswanathan of "RBC Capital" Maintained at Buy with Increased Target to $45 on, Monday, November 8th, 2021
Contributing Sources